March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor 

The European Commission approved Kesimpta ofatumumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms of multiple sclerosis. The subcutaneously administered drug was originally developed by Genmab A/S (CSE:GMAB; NASDAQ:GMAB).

Evrysdi risdiplam, an oral small molecule SMN2 splicing modifier from Roche (SIX:ROG; OTCQX:RHHBY), was authorized in the EU to treat 5q spinal muscular atrophy in patients ages two months and older with Type 1, Type 2 or Type 3 disease, or one to four SMN2 copies. The pharma holds Evrysdi’s rights from PTC Therapeutics Inc. (NASDAQ:PTCT). Roche’s Genentech Inc. unit virtually launched the drug the midst of COVID-19...